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The Perspective by Pallotta et al. (1) offers
the opportunity of a few more con-
siderations on the mutually supportive
relationship between tryptophan catabolic
enzymes and the aryl hydrocarbon receptor
(AhR) in the transitional response aimed
at reinstalling homeostatic tolerance after
meeting the needs of an acute inflamma-
tory reaction (2). One major question is
in fact – Why does AhR need two dis-
tinct sources of the ligand kynurenine to
become activated, namely, tryptophan 2,3-
dioxygenase (TDO2) and indoleamine 2,3-
dioxygenase (IDO1) (3)? (The third known
tryptophan catabolic enzyme, IDO2, has
limited catalytic activity relative to the two
others.).
The IDO1–AhR axis would, in fact,
appear to be a highly efficient mechanism
per se, in that it acts in a feedforward loop
[i.e., kynurenine is an activating ligand for
AhR, and activated AhR promotes Ido1
transcription (4)], and it is self-regulated
[AhR presides over regulatory proteolysis
of IDO1, to restore homeostasis, as pro-
posed by Pallotta et al. (1)]. For this loop to
be operative, one need must be absolutely
met, namely, the absence of IL-6, which
operates its own mode of IDO1 proteaso-
mal degradation via induction of SOCS3,
resulting in the enzyme ubiquitination and
proteolysis (5). Although it is one of AhR’s
multiple jobs to transcriptionally repress
FIGURE 1 | Sequential events marking the transitional response aimed at reinstalling
homeostatic tolerance after meeting the needs of an acute inflammatory reaction, withTDO2
and IDO1 having temporally segregated roles.
Il6 – through transcription of Il10 (6) –
the AhR–IDO1 system is IL-6-sensitive,
and the “early” kynurenine leading to
the recruitment of IL-10 to the transi-
tional response must derive from a source
other than the IDO1–AhR axis, that is,
an enzyme not amenable to suppression
by IL-6.
At the onset of an inflammatory
response, IL-6 production is a necessary,
defensive mechanism that need not be
abrogated till the onset of the transition
that will contribute to reinstall an optimal
balance between inflammation and toler-
ance. Among the early events of systemic
inflammation is cortisol-driven induction
of acute phase proteins in liver. TDO2 is
one such protein, and it is synthesized
when production of proinflammatory
cytokines, including IL-6, is at its height.
Tdo2 is not under AhR transcriptional con-
trol, nor is TDO2 amenable to IL-6-driven
proteasomal degradation (3). This makes
TDO2 production of kynurenine – and
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AhR activation – compatible with the
events initiating the transitional response
(Figure 1).
The conclusion is that the roles of TDO2
and IDO1 as a source of AhR ligands are
not redundant, the major differences lying
in the different modalities of their respec-
tive gene activation, their being temporally
segregated in function, and their disparate
susceptibilities to inhibition by IL-6.
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